肝癌增强子-miRNA调控作用对的识别与特征分析

目的：探讨肝癌和正常肝组织中增强子与miRNA形成的调控关系及调控miRNA的增强子的特征，筛选出由增强子调控的差异表达miRNA并探讨其与肝癌治疗靶点的相关性。方法：基于TCGA与FANTOM5 数据库，对肝癌和正常肝组织中共417 个样本的增强子与miRNA进行共表达与3D基因组分析得到调控关系。通过ENCODE数据库中肝癌与正常肝组织的组蛋白修饰与转录因子的ChIP-seq 数据分析调控miRNA的增强子上信号值的差异。筛选由增强子调控的差异表达的miRNA，并对患者的生存期与治疗靶点进行相关性分析。结果：在肝癌与正常肝组织中分别识别增强子-miRNA 作用对93 对和40 对。ChIP-seq 数据比对分析发现，肝癌中组蛋白修饰H3K27ac、H3K4me1 和H3K4me3 信号在调控miRNA增强子区域显著高于不调控miRNA的增强子区域（|rho|>0.3，P<0.05）；多种转录因子在肝癌相关增强子中的富集显著低于正常肝组织（|rho|>0.3，P<0.05）。对增强子调控的miRNA进行差异表达分析，识别了6个与肝癌患者生存相关miRNA（hsa-miR-4664、hsa-miR-5003、hsa-miR-1915、hsa-miR-3619、hsa-miR-4745、hsa-miR-6728），发现这些miRNA 与87 个用于靶向治疗的基因以及8 个免疫检查点基因显著相关（|rho|>0.1，FDR<0.05）。结论：成功在肝癌中识别出增强子-miRNA调控作用对与调控miRNA的增强子的特征，并筛选出由增强子调控的与肝癌患者生存和治疗靶点相关的miRNA，为后续深入开展肝癌的基础与临床研究提供了参考依据。     

球囊导管取栓术治疗急性下肢动脉栓塞患者的体会

目的探讨球囊导管取栓术治疗急性下肢动脉栓塞患者的临床疗效。方法回顾性分析祈福医院2013年1月至2018年12月应用球囊导管微创取栓术治疗的78例急性下肢动脉栓塞患者的临床资料。结果治愈60例,治愈率为89.6%,患肢血供恢复。好转7例(10.4%),肢体缺血症状明显好转。全部患者无截肢。死亡1例(2.6%)。结论球囊导管取栓术是治疗急性动脉栓塞的有效方法,患者一经确诊应尽早手术取栓,有利于提高其保肢率和降低病死率。     

A Rare Case of Late LAD Reimplantation after Arterial Switch Operation

Arterial switch operation (ASO) is a complex neonatal operation in which transfer of the coronary arteries origins is the key to success. Coronary events after a successful ASO are not uncommon. We describe a rare case of a child who underwent an ASO in the neonatal period with one coronary (LAD) described as atretic left in place. At age seven, he developed myocardial ischemia due to retrograde flow with a steal phenomenon from the LAD into the pulmonary artery. The patient underwent a late LAD reimplantation. This case underscores that even very small ostia should be translocated at the time of ASO.     

基于NDR评分评估多发性肝癌根治术后经导管动脉化疗栓塞治疗效果研究

目的 探讨NDR评分与多发性肝癌肝切除术后经导管动脉化疗栓塞术（TACE）疗效的关系。方法 回顾性分析2009年3月至2015年3月在海军军医大学东方肝胆外科医院行肝切除术的505例多发性肝癌病人的临床资料。根据术后是否行辅助性TACE将病人分为TACE组（n=272）和非TACE组（n=233），采用倾向得分匹配（PSM）对病人行1∶1配对。应用Kaplan-Meier法分析术后无复发存活率（RFS）和总体存活率（OS）的差异，并分析NDR评分与TACE疗效的关系。结果 PSM后，TACE组1、3、5年RFS和OS均高于非TACE组（66.8%、41.2%和27.6%；49.6%、37.2%和27.7%，P=0.031；86.1%、63.7%和42.6%；69.1%、49.0%和37.2%，P=0.002）。NDR评分≤2分时，TACE 组1、3、5年RFS和OS与非 TACE 组差异无统计学意义（68.6%、44.1%、29.0% vs. 58.0%、43.3%、35.2%，P=0.445；88.3%、65.0%、44.4% vs. 76.4%、55.0%、45.7%，P=0.109）；NDR评分>2分时，TACE 组1、3、5年RFS和OS均高于非TACE组（60.5%、34.2%、28.5% vs. 20.3%、16.2%、8.1%，P=0.001；78.9%、51.6%、42.8% vs. 43.8%、29.9%、15.9%，P=0.007）。PSM后NDR评分>2分时，多因素分析显示，甲胎蛋白（AFP）和辅助性TACE是无复发生存的独立影响因素（HR=1.90、0.43；P<0.05）；AFP、肿瘤最大最小径比值和辅助性TACE是总体生存的独立影响因素（HR=2.23、2.96、0.53；P<0.05）。结论 NDR评分>2分时，肝癌肝切除术后行辅助性TACE可有效减少术后复发，改善远期生存。对NDR评分>2分的多发性肝癌病人，推荐辅助性TACE作为术后抗复发治疗手段。     

Comparison of inhaled nitric oxide with aerosolized prostacyclin or analogues for the postoperative management of pulmonary hypertension: a systematic review and meta-analysis

Abstract

Background: This study aims to compare the effectiveness of inhaled prostacyclin or its analoguesversus nitric oxide (NO) in treating pulmonary hypertension (PH) after cardiac or pulmonary surgery remains unclear.

Methods: PubMed, Cochrane, and Embase databases were searched for literature published prior to December 2019 using the following keywords: inhaled, nitric oxide, prostacyclin, iloprost, treprostinil, epoprostenol, Tyvaso, flolan, and pulmonary hypertension. Randomized controlled trials and multiple-armed prospective studies that evaluated inhaled NO versus prostacyclin (or analogues) in patients for perioperative and/or postoperative PH after either cardiac or pulmonary surgery were included. Retrospective studies, reviews, letters, comments, editorials, and case reports were excluded.

Results: Seven studies with a total of 195 patients were included. No difference in the improvement of mean pulmonary arterial pressure (pooled difference in mean change= ?0.10, 95% CI: ?3.98 to 3.78, p?=?.959) or pulmonary vascular resistance (pooled standardized difference in mean change= ?0.27, 95% CI: ?0.60 to 0.05, p?=?.099) were found between the two treatments. Similarly, no difference was found in other outcomes between the two treatments or subgroup analysis.

Conclusions: Inhaled prostacyclin (or analogues) was comparable to inhaled NO in treating PH after cardiac or pulmonary surgery.

• Key messages

• This study compared the efficacy of inhaled prostacyclin or its analogues versus inhaled NO to treat PH after surgery. The two types of agent exhibited similar efficacy in managing MPAP, PVR, heart rate, and cardiac output was observed.

• Inhaled prostacyclin may serve as an alternative treatment option for PH after cardiac or pulmonary surgery.

     

姑息性大动脉调转手术的麻醉管理

目的 总结姑息性大动脉调转手术(palliative arterial switch operation,PASO)的麻醉管理. 方法 回顾性总结分析28例于我院行PASO的完全性大动脉转位合并室间隔缺损(transposition of the great arteries with ventricular septal defect,TGA/VSD)或Taussing-Bing综合征患者的临床资料.28例患者年龄中位数为4岁(1月～25岁),体重中位数为12.5 kg(3.6～43kg),术前均诊断为重度肺动脉高压,术前SpO2波动在44％～91％. 结果 所有患者麻醉过程平稳,平均CPB时间为(223±81) min,平均主动脉阻断时间为(153±32) min.平均室间隔补片留孔大小为(5.3±1.5) mm.术后机械辅助通气时间中位数为36 h(7～408 h),ICU停留时间中位数为5.5 d(2～27 d).术后平均SpO2为(96±2)％,与术前比较,差异有统计学意义(P＜0.05).住院死亡5例(18％),余好转出院.出院患者中5例在出院后的1～5年间行介入残余室缺分流堵闭术. 结论 充分的术前准备和评估,平顺的麻醉诱导和维持,围手术期肺动脉高压的处理,早期合理地应用血管活性药物以及出凝血功能的调整,有利于PASO的成功.